Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. Among authors: sheikh sz. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B. Ginzler E, et al. Arthritis Rheumatol. 2022 Jan;74(1):112-123. doi: 10.1002/art.41900. Epub 2021 Dec 9. Arthritis Rheumatol. 2022. PMID: 34164944 Free PMC article. Clinical Trial.
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.
Sheikh SZ, Scheinberg MA, Wei JC, Tegzova D, Stohl W, de Toledo RA, Mucenic T, Banfi MRA, Maksimowicz-McKinnon K, Abud-Mendoza C, Navarra S, Garcia M, Garcia-De La Torre I, Ros JO, Levy RA, Bass DL, Terrés JR, Punwaney R, Harris J, Nami A, Pierce A, Thorneloe KS, Ji B, Roth DA. Sheikh SZ, et al. Lancet Rheumatol. 2021 Feb;3(2):e122-e130. doi: 10.1016/S2665-9913(20)30355-6. Epub 2020 Dec 15. Lancet Rheumatol. 2021. PMID: 38279368
A Provider-Based Approach to Address Racial Disparities in Lupus Clinical Trial Participation.
Wanty NI, Cooper DL, Simkus A, Twombly EC, McCalla S, Holtz SKD, Langford AT, Cozart T, Gorlitsky B, Moore C, Culton D, Richardson CT, Wardrop RM, Newcomb J, Aranow C, Lim S, Anandarajah A, Sheikh SZ. Wanty NI, et al. Among authors: sheikh sz. Arthritis Care Res (Hoboken). 2023 Jul;75(7):1434-1442. doi: 10.1002/acr.25054. Epub 2023 Jan 23. Arthritis Care Res (Hoboken). 2023. PMID: 36342382
Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies.
Williams JN, Dall'Era M, Lim SS, Feldman CH, Arntsen KA, Blazer AD, Goode T, Merrill JT, Sheikh S, Stevens AM, Lipsky PE, Costenbader KH. Williams JN, et al. Arthritis Care Res (Hoboken). 2022 Mar;74(3):420-426. doi: 10.1002/acr.24474. Epub 2022 Jan 19. Arthritis Care Res (Hoboken). 2022. PMID: 33026693 Free PMC article.
77 results